Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Breast 16Genitourinary 15Dermatologic 4Tumor-Agnostic 3Plasma cell 3Lymphoid 3Head & Neck 3Thoracic 2Other hematologic neoplasm 2Gynecologic 2Gastrointestinal 2CNS 2Sarcoma 1Other solid neoplasm 1Myeloid 1Endocrine 1

Conditions

Melanoma 3Wilms Tumor 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Pain 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphedema 1Kidney Neoplasms 1Hepatoblastoma 1Endometrial Neoplasms 1Desmoid Tumors 1Depression 1Colorectal Neoplasms 1Clinical Stage III Cutaneous Melanoma AJCC v8 1Cicatrix 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Absorptiometry, Photon × Dermatologic × Clear all
NCT07555210 2026-05-06

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Vanderbilt-Ingram Cancer Center

Phase NA Recruiting
25 enrolled
BreastDermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma, Triple Negative Breast Neoplasms

NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

NCT04516122 2025-08-17

Bone Loss in Melanoma Survivors Receiving Immunotherapy

M.D. Anderson Cancer Center

Terminated
12 enrolled
Dermatologic

Clinical Stage III Cutaneous Melanoma AJCC v8

NCT02352623 2016-05-26

Quality of Life and Surgical Late Effects of Melanoma Treatment

Herlev Hospital

Completed
435 enrolled
Dermatologic

Anxiety Disorders, Cicatrix, Depression, Lymphedema, Melanoma, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡